Replies to post #421393 on Anavex Life Sciences Corp (AVXL)

[Hoskuld]

Because Anavex eschewed investment bank financing in favor of far less costly and less dilutive funding methods, institutional interest is low and incentives for IBs to support the stock are non-existent. In the end, this will not matter but along the way it can be a little painful.

[Steady_T]

Most of that I suspect is due to Anavex's unconventional approach to treating AD.
The MOA is a completely new mechanism in terms of CNS disease.

Most approaches take aim at the most visible effects of AD, the plaques and the tangles.
Anavex is going way upstream in the disease process. At this point most science can't agree on what the disease process actually is. That creates a lot of skepticism.

Once 2-73 is approved and the full AD data is published, the disease mechanism proposed by Anavex will be taken far more seriously. We are already seeing some of that in the increased research on the Sigma 1 receptor that is being published.

Essentially Anavex is set up for a threshold event. Rather like an avalanche. Nothing happening till that last show flake hits then some snow starts moving down hill, increasing in momentum and volume as it goes.